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The aims of the study were: 1) the evaluation of the agreement between therapeutic drug monitoring 
(TDM) and a self-assessment of adherence to psychopharmacological treatments; 2) the identification 
of predictors of TDM results. Adherence admitted into a psychiatric emergency service (PES) for a 
relapse of a schizophrenia spectrum disorder (SSD) or a bipolar disorder (BD; DSM-5) was assessed 
both directly with TDM and indirectly with a self-reported measure (Medication Adherence Report 
Scale -MARS- 10 items).  The agreement between TDM and MARS was evaluated. Fifty-seven 
patients with SSD and 76 people with BD participated in the study. TDM was in range in about 50% 
of the global sample. No evidence of an association between MARS total scores and TDM results 
was found. Sensibility, specificity, positive and negative predictive values of almost all MARS total 
scores were near to 50%. Smoking was strongly associated with a reduction of TDM results within 
the reference range. In the BD group, female sex was a predictor of TDM in range. In this clinical 
setting, self-assessment of adherence is neither reliable nor predictive. Furthermore, smoking is a 
strong predictor of poor adherence to psychopharmacological therapy.  
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1. Introduction  
    Adherence to treatments, defined as the extent to which a person’s behavior (taking 
medication, following a diet, and/or executing lifestyle changes) corresponds with agreed 
recommendations from a health care provider, is often inadequate in chronic medical conditions as 
up to 50% of patients have no or only partial adherence (Sabaté,2003). In mental health, data are 
similar showing that up to 70% of people living with a mental disorder have an inadequate 
adherence to treatments (Haddad et al.,2014; Higashi et al.,2013; Murru et al.,2013).  Adherence 
is a multidimensional phenomenon influenced by several elements: patient, illness, and treatment 
related factors, therapeutic alliance and engagement with health services, quality of mental health 
services, economic and social factors (Buchman-Wildbaum et al.,2020; Leclerc et al.,2013; Leucht 
e Heres, 2006; Kane e Correll, 2010; Velligan et al., 2017). In schizophrenia spectrum disorders 
(SSD) and bipolar disorders (BD), adherence appears to be negatively affected by cannabis 
(Schoeler et al., 2017), alcohol and substance use (Velligan et al.,2017), treatment-related side-
effects (Pompili et al.,2013), impaired insight (Novick et al.,2015; Kim et al,2020; Velligan et 
al.,2017) cognitive deficits (Velligan et al.,2017), internalized stigma (Buchman-Wildbaum et 
al.,2020; Kamaradova et al.,2016: Verdoux et al., 2020), lower quality of life (Buchman-Wildbaum 
et al.,2020; Verdoux et al., 2020), stage of recovery, and mental well-being (Verdoux et al., 2020), 
and higher levels of hostility (Czbor et al.,2015;Novick et al.,2010). Conversely, it seems to be 
positively influenced by positive attitudes to medications (Sendt et al.,2015), therapeutic alliance 
(Novick et al.,2015; Pompili et al.,2013), and family support (Saba et al.,2019).   
 Partial or non-adherence to treatments negatively affects the evolution of SSD and BD, with 
greater frequency of relapses, reduction of response to psychopharmacological therapies, 
progressive chronicity of symptoms, higher suicide risk, and worsening of real-life functioning 
(Alvarez-Jimenez etal.,2012; Levin et al.,2016; Pompili et al.,2009). Poor adherence to treatments 
is one of the only modifiable relapse risk factors (Emsley et al.,2013), therefore needs to be 
constantly monitored and addressed by acting on its determinants (Acosta et al.,2012; Kini e 
Ho,2018). Moreover, in case of relapse, it is crucial to differentiate between resistance to treatment 
and pseudo-resistance, due to inadequate adherence or substances interactions, as these two 
different scenarios could lead to different therapeutic choices (Dold e Leucht,2014; Fornaro et al., 
2020; Kane et al., 2019).  
 Adherence can be measured by direct or indirect methods. Direct methods most widely 
applied are direct observed therapy and therapeutic drug monitoring (TDM). Indirect measures 
include objective and subjective evaluations. Objective methods are electronic drug monitoring, 
rate of prescriptions refill, clinical response evaluation, monitoring of markers of treatment effects. 
Subjective evaluations are represented by patients’, caregivers’, or health care professionals’ 
estimate of adherence (Kane e Correll,2010, Osterberg e Blaschke,2005; Sajatovic et al.,2010, 
Velligan et al.,2020). Direct methods, in particular TDM, are generally more sensitive and specific 
than indirect ones but are not extensively adopted in everyday clinical practice for practical and 
economic reasons (Kane et al.,2019; Osterberg et Blaschke,2005; Velligan et al., 2020). On the 
contrary, self-assessment of adherence to therapy is one of the most used, practical, and cheap 
methods to evaluate compliance with psychopharmacological treatment but is often affected by 
patients’ lack of awareness of the need of a continuous psychopharmacological treatment (Kane e 
Correll,2010; Kim et al.,2020; Novick et al. 2015; Sajatovic et al.,2010; Velligan et al.,2020). 
Indeed, insight deficit is a prevalent feature of SSD (Amador et al.,1994; Belvederi Murri e 
Amore,2019) also found in BD (Látalová,2012), and includes unawareness of symptoms, treatment 
need, and alterations in cognitive processes involved in the capacity for self-reflectiveness and self-
evaluation (Dias et al., 2008; Elowe e Conus, 2017: Medalia e Thysen, 2010: Pini et al., 2001). 
  
   Following the World Health Organization recommendation to combine both direct and indirect 
methods to accurately assess adherence (Sabaté,2003), and the lack of scientific evidence of this 
multimodal evaluation in a real word setting of emergency psychiatry, we decided to study the 
compliance with psychopharmacological therapy of patients with SSD and BD recently admitted in 
a psychiatric emergency service (PES). In particular, the aims of the present study are: 1) to evaluate 
the agreement between an objective (TDM) and a subjective (self-assessment) evaluation of 
adherence to the psychopharmacological treatments; 2) to assess which socio-demographic and 
clinical variables can predict treatment adherence determined with TDM. 
2 Methods 
 The present work was conducted in the Psychiatric Emergency Service (PES) “Struttura 
Complessa Psichiatria – Servizio Psichiatrico di Diagnosi e Cura” (SPDC) of the Departmentof 
Neuroscience and Mental Health of “Città della Salute e della Scienza” hospital of Turin, Italy, in the 
period between February 2019 and November 2020.  
2.1 Subjects 
 All patients consecutively admitted who fulfilled inclusion criteria were included in the study. 
  
 Inclusion criteria were the following: a) diagnosis of schizophrenia spectrum disorders (SSD) 
or diagnosis of bipolar and related disorders (BD), according to DSM-5 diagnostic criteria; b) age 
over 18 years; c) being in therapy, at the admission time, with a drug whose concentration in the 
serum could be evaluated at the hospital laboratory: lithium, sodium valproate, carbamazepine, 
haloperidol, clozapine, olanzapine, risperidone, paliperidone, quetiapine, aripiprazole.  For 
patients with psychiatric polypharmacotherapy we measured only one drug: i.e., the only 
antipsychotic or mood stabilizer prescribed with a daily dosage indicated for the treatment of the SSD 
or of the BD according to the technical data sheet of that drug. When this selection of a single drug 
was not applicable, patients were not included in the study.  
   Exclusion criteria were the following: a) co-presence of a diagnosis of dementia, delirium or 
intellectual disability; b) standard informed consent to treatments and standard personal data 
collection consent not provided by patient or his legal representative, c) concomitant treatment with 
a drug pharmacokinetically interacting with the drug assessed with TDM according to the technical 
data sheet of at least one of the two drugs; d) admission for psychotropic drug intoxication.    
 To avoid duplication, only data for the first hospitalization of patients who had multiple 
hospitalizations were included in this analysis.  
 The study was carried out in accordance with the principles of the Declaration of Helsinki 
(with amendments) and of the Good Clinical Practice and was approved by the Local Research Ethical 
Committee (LREC; in Italian Comitato Etico Interaziendale – CEI – n.185). The study protocol was 
integrated in the regular diagnostic assessment and did not imply any variation from standard care 
usually provided in the recruiting unit. Data were analyzed anonymously as all personally sensitive 
information was de-identified in the dataset, according to the Italian legislation. According to these 
characteristics of the study protocol, the LREC agreed that a study specific informed consent, 
additional to the standard ones used in the clinical practice of the PES, was not required.   
2.2 Clinical assessment 
 Socio-demographic and clinical variables were assessed through a semi-structured interview. 
Psychiatric symptoms were rated with the Italian version of the Brief Psychiatric Rating Scale (BPRS) 
(Overall,1974) which encodes 5 sub-scales evaluating different psychopathological dimensions 
(Shafer,2005): BPRS-1, Affect (anxiety, guilt, depression, somatic symptoms); BPRS-2, Negative 
Symptoms (blunted affect, emotional withdrawal, motor retardation); BPRS-3, Positive Symptoms 
(unusual thought content, conceptual disorganization, hallucinatory behavior, grandiosity); BPRS-4, 
Activation (excitement, tension, mannerisms–posturing); BPRS-5, Resistance (hostility, 
uncooperativeness, suspiciousness). The global severity of symptoms was estimated with the Clinical 
Global Impression – Severity scale (CGI-S) (Guy,1976), the engagement with psychiatric services 
with the Services Engagement Scale (SES)  where a higher total score indicates a lower engagement 
(Tait et al.,2004), the global functioning, prior to the clinical relapse that led to hospitalization, with 
the Global Assessment of Functioning scale (GAF) (Goldman et al.,1992), and the 
psychopharmacological treatment side effects with the Udvalg for Kliniske Undersøgelser - Side 
Effect Rating Scale (UKU) (Lingjaerde et al.1987).   
 All assessments were performed by the same well-trained experienced interviewing 
psychiatrists (C.B. and F.P.). To reduce inter-rater variability, raters were trained to administer the 
psychometric tools according to common standards. Efforts were made to maintain inter-rater 
reliability across the entire study period, including careful standardization of the procedures and 
regular, in-depth review of a sample of interviews with the lead authors (P.R. and V.V.). 
2.3 Evaluation of the adherence to the psychopharmacological treatment 
 An objective and a subjective self-evaluated measure of adherence to the 
psychopharmacological treatment were performed.  
 TDM has been performed at the admission in the unit or, when not possible, before the first 
assumption of the drug monitored. Ultra-high-performance liquid chromatography–tandem mass 
spectrometry (UHPLC-MS/MS) was used to assess serum drug concentration. The only exception 
was lithium ion whose concentration was measured with ion selective electrodes (ISE). According to 
the methods proposed by the Consensus Guidelines for Therapeutic Drug Monitoring in 
Neuropsychopharmacology: Update 2017 (Hiemke et al.,2018) dose-related reference range (DRRR) 
were calculated for each drug measured. Patients whose plasmatic drug concentration was within the 
DRRR have been classified in the group of TDM in range (TDM-iR), while those with drug 
concentration out of the DRRR have been divided into TDM below the range (TDM-bR) and TDM 
above the range (TDM-aR).   
 Subjective self-assessment of adherence to treatment was evaluated with the Medication 
Adherence Rating Scale (MARS); (Thompson et al. 2000). The MARS is a 10-item self-administered 
questionnaire designed to be simple and easy to complete in any clinical context.  It assesses 
medication adherence behavior (items 1–4), attitude toward taking medication (items 5–8), and 
negative side effects to psychotropic medication (items 9–10) (Verdoux et al., 2020). Total MARS 
score ranges between 0 and 10. Higher scores indicate better adherence.  
2.4 Statistical analysis 
  Agreement between TDM and MARS total score was analyzed with point-biserial 
correlation (rpb). Two ROC curves (SSD and BD groups) were built using TDM as gold standard and 
MARS total scores. Their areas under the curve (AUC) were compared with each other and with the 
random classification. Sensitivity (Sens), specificity (Spec), accuracy (Acc), positive predictive value 
(PPV), negative predictive value (NPV), positive likelihood ratio (+LR), and negative likelihood ratio 
(-LR) with 95% confidence interval (95% CI) were calculated for each MARS total score value. 
  
 Univariate analyzes were carried out to compare the two clinical groups (SSD vs BD), and 
adherent and non-adherent patients according to the TDM (TDM-iR vs TDM-b/aR). TMD results 
were reported for each drug measured and a comparison between all antipsychotics and all mood 
stabilizers was performed. For these comparisons, analysis of variance (One-way ANOVA) for 
continuous variables and the χ2 test for categorical variables were employed.    A multivariate 
backward logistic regression was performed for each clinical group to assess which variables were 
most strongly associated with TDM-iR. Only the variables statistically different in univariate analyses 
were included in the two regression models. The amount of variation in the dependent variable 
explained by the model in terms of accuracy of the prediction was estimated with the Nagelkerke's 
pseudo-R2 index.   
 Statistical analyses were performed using the Software System Statistical Package for the 
Social Sciences (SPSS), version 27 for Windows. Statistical significance was set at p < .05 for all 
analysis. Variables maintained in the regression models were consider significant if they were 
associated with a p-value < .1.   
3. Results  
3.1 Characteristics of participants and TDM results 
 Socio-demographic, clinical, psychopathological, and treatment-related variables of the two 
clinical groups are illustrated in table 1.   
  TDM was in range in about half of the global sample.  No TDM result was above the 
DRRR, therefore all TDM results out of the DRRR were below the range (TDM-bR). The mean total 
score of the MARS was 5.6 in both clinical groups, meaning that, on average, patients self-assessed 
themselves as non-adherent to psychopharmacological treatment in 4 or 5 items of the scale.   
 TDM results for each drug monitored are shown in table 2. There was not statistically 
significant difference between adherence to antipsychotics and mood stabilizer (χ2 = 1.095; p = .295).  
3.2 Agreement between direct (TDM) and indirect subjective (MARS) evaluation of adherence  
 No significant results were found with the point-biserial correlation in both clinical groups 
(SSD: rpb = .155, p = .250; BD: rpb = .059, p = .613). According to our data, there is no evidence of 
an association between the MARS total score and TDM results (fig. 1).   
 The ROC curves of the two clinical groups are displayed in figure 2. There was no statistical 
difference between the AUC of the two curves and the overall quality of two models was less than 
0.5 (SSD = 0.43; DB = 0.41), meaning that the two models were not better than random prediction.  
Similarly, Acc, Sens, Spec, PPV, and NPP were near to 50 % (random prediction) for almost all 
values of MARS total score in both SDD and DB groups (tab .3). +LR and -LR were mostly near to 
1, indicating poor performance of any score of the MARS in correctly identify patients’ adherence.   
3.3 Differences between subjects with TDM-iR and TDM-bR and predictors of adherence assessed 
with TDM  
 Sociodemographic, clinical, psychopathological, and psychopharmacological treatment 
related variables of the SDD and BD clinical groups divided into sub-groups according to TDM 
results (TDM-iR vs TDM-bR) are shown in table 4.   
 In the SSD group, the logistic regression model (tab. 5) was highly significant (χ2 = 11.801; p 
= .003). A lower engagement was associated with a small reduction (OR = .936; p = .077) of treatment 
adherence (TDM-iR) whereas cigarette smoking was strongly associated with a marked reduction of 
TDM-iR (OR = .196; p = .008). This model demonstrated a total accuracy in predicting TDM iR or 
bR of 64.9%, a greater ability in predicting TDM-bR (71.4%), and lower precision in the prediction 
of TDM-iR (58.6%). The amount of variation of TDM estimated with the Nagelkerke's pseudo-R2 
index was 24.9.  
 The logistic regression model of patients with BD (tab. 5) was highly significant (χ2 = 12.134; 
p = .002). Female sex was associated with an important increase (OR = 2.671; p = .055) of treatment 
adherence evaluated with TDM. Cigarette smoking was associated with a marked reduction of TDM-
iR (OR = .273; p = .016). The total accuracy of the model in predicting TDM iR or bR was 65.8% 
with a greater ability in predicting TDM-iR (73.8%), and a lower precision in the prediction of TDM-
bR (55.9%). The Nagelkerke's index was 19.7%.  
4. Discussion 
 Main findings  
 To our knowledge, this the first study to evaluate the agreement between the results of an 
objective and reliable direct measure of adherence (ultra-sensitive TDM) with a self-assessed indirect 
one (MARS) in a real-world setting of psychiatric emergency ward, in both patients with SSD and 
BD, that was the first aim of the study. Furthermore, as second aim, this work tried to find out 
predictors of adherence evaluated with ultra-sensitive TDM.       
  
 Concerning the first aim, our results demonstrated poor concordance between self-reported 
and direct measures of adherence in both SSD and BD groups: as clearly graphically represented in 
figure 1, point-biserial correlation (rpb) was not statistically significant. These data suggest that 
patients, during a relapse, have marked problems in reporting their adherence to the 
psychopharmacological treatment. They also indicate that self-reporting is not informative 
irrespective of the direct measure of adherence (TDM) as shown in figure 1. This finding is in line 
with previous studies demonstrating that patients were inaccurate raters of their adherence to 
psychopharmacological therapy (Kane e Correll 2010; Velligan et al.,2017; Kim et al.,2020; Novick 
et al.,2015; Sajatovic et al.,2010; Velligan et al.,2020; Lopez et al.,2017).  This difficulty in 
self-evaluation can have multiple reasons including metacognitive and insight deficits, 
misunderstanding the items on a rating scale, and inaccurately conceptualizing correct compliance 
with therapies. These types of errors could derive from cognitive deficits, from the severity of specific 
symptomatic dimensions, and from the socio-demographic characteristics of the patients. Focusing 
on the lack of insight, prior to the onset of the relapse, patients could underestimate the constant need 
of psychopharmacological therapy, even during a period of psychic wellbeing.  Then, during the onset 
of the relapse a further reduction in the awareness of the need for proper treatment could induce an 
additional worsening of adherence, thus precipitating the clinical condition into a full-blown 
recurrence of illness.  Finally, at the beginning of the hospitalization in the PES, mechanism other 
than insight reduction could influence the untrustworthiness of patients’ self-assessment of 
adherence, e.g., an increase of psychotic or manic symptoms, and the fear to be blamed for poor 
compliance with therapies. In accordance with these suppositions, several studies attributed a 
central role to the insight in determining adherence to psychopharmacological therapies (Kane e 
Correll, 2017; Velligan et al.,2017; Kim et al.,2020;  Novick et al.,2020; Sajatovic et al.,2010; 
Velligan et al.,2020).   
 As direct consequence of the mismatch found between direct and self-assessed evaluations of 
adherence, it was not possible to identify a reliable MARS threshold value suitable to identify subjects 
with TDM-uR or TDM-iR. Likewise, the ROC curves of the SSD and BD groups were similar and 
both close to random prediction. Consequently, almost all PPVs and NPVs were unreliable (about 
50% of correct predictions) for any MARS score. Hence, according to our data, in the clinical setting 
of a PES, MARS is not a suitable instrument to evaluate adherence to psychopharmacological 
treatment and consequently to distinguish between “actual” and pseudo-resistance.  
 Therefore, the evaluation of resistance to psychopharmacological therapy could be supported 
by TDM, which however entails costs and delays often not compatible with the clinical setting of and 
emergency psychiatry ward, where rapid and appropriate therapeutic decisions, frequently based on 
the distinction between “actual” and pseudo-resistance, are needed (Kane e Correll, 2010; Osterberg 
e Blaschke,2005; Velligan et al.,2020). These limits lead to the second objective of this work, namely 
the possibility of predicting, based on variables available at the admission into the PES, the result of 
the TDM and therefore to distinguish between “actual” and pseudo-resistance.   
 As regards the second aim, smoking more than 10 cigarettes a day was the strongest predictor 
of poor adherence evaluated with TDM in both SSD and BD groups. This negative association may 
have several explanations including: 1) smoking could increase the rate of metabolization of the drug 
by induction of cytochromes p-450 (CYPs) at liver level; 2) patients with more severe symptoms, 
such as during the onset of a relapse, might increase cigarette consumption with the aim of alleviating 
psychic suffering, thus increasing the induction of cytochromes; 3) an indirect relationship between 
smoking and the decrease in plasma concentrations of drugs. These three hypotheses can occur 
simultaneously and partly explain what is observed in our study. Concerning hypothesis 1 and 2, i.e., 
direct effect of cigarette smoking, polycyclic aromatic hydrocarbons found in tobacco induce 
CYP1A2. This enzyme metabolizes olanzapine and clozapine, thus reducing their serum 
concentration (Hiemke et al.,2018; Faber et al.,2005, Haslemo et al.,2006; Tsuda et al.,2014). 
Hypothesis 3, i.e., indirect relationship, can be explained with complex interplays among many 
different factors. Patients with more severe psychiatric disorders and symptoms tend to smoke more 
and vice versa. As compared to non-smokers leaving with a severe mental illness (SMI), smokers 
suffering from a SMI have poorer economic conditions, cognitive performance, prognosis, global 
functioning, quality of life, and subjective wellbeing (Caponnetto et al.,2020; Depp et al.,2015; Firth 
et al.,2020; Medeiros et al.,2018; Prochaska et al.,2017; Thomson et al.,2015; Wang et al.,2019). This 
illness- and patient-related characteristics could lead to a lower level of insight in terms of need for 
treatment, thus facilitating the poor adherence. At the same time, this clinical population has a greater 
prevalence of unhealthy lifestyles habits as alcohol and substance use. This facilitates the prevalence 
of medical comorbidities and the need to take many different medications (Firth et al.,2020; 
Prochaska et al.,2017; Thomson et al.,2015). In this view, substance-drug or drug-drug 
pharmacokinetic interactions are more likely, resulting in sub-therapeutic serum concentration of 
psychopharmacological treatments.   
 In the SSD group, a higher SES score (i.e., lower service engagement) was associated with 
poor adherence (TDM-uR). This result agrees with the study of Kini et at al. 2018, according to which 
a good therapeutic alliance and a solid service engagement positively influence patients’ compliance 
to treatments (Kini e Ho, 2018). Simultaneously, female sex in patients with BD was a strong 
predictor of good adherence (TDM-iR). This result is in line with previous findings that showed that 
women were more precise in taking the therapies prescribed (Gonzales-Pinto et al.,2006). 
  
 The two regression models were able to correctly classify as adherent or non-adherent, 
according to TDM results, about 65% of patients. This value is higher than random prediction, 
however far from a safe and certain forecast and in line with the relatively low psudo-R2 indices (20-
25%). Better prediction, over 70%, were found in predicting poor adherence in the SSD group and 
good adherence in the BD patients. The psudo-R2 indices values could be partly explained by non-
behavioral determinants of TDM-uR (Sutherland et al.,2018) like drug-drug interactions, not signaled 
in the technical data sheet or due to the interaction between more than two drugs, and patient related 
biological factors affecting pharmacokinetics of psychopharmacological treatment such as CYPs and 
ATP-binding cassette sub-family B member 1(ABCB1) genes, the formers coding for cytochromes 
P450 and the latter for permeability glycoprotein 1 (PGP1), also known as multidrug resistance 
protein 1 (MDR1). 
 Strengths and limitations 
 The main limitations of the present study are the lack of data that clearly explain the strong 
relationship between smoking and poor adherence, and the relatively small values of the pseudo-R2 
indices of the regression models.  
 Despite these limitations, this study has some important strengths: firstly, the naturalistic 
design in a real-world setting of psychiatric emergency focusing on a sample of acute inpatients, 
poorly represented in literature on adherence, which considers more frequently outpatients, and 
secondly the use of ultra-sensitive TDM for haloperidol and different second-generation 
antipsychotics, which is poorly studied and employed in clinical practice. 
 Future perspectives and implications 
 For further research, analysis of genes involved in pharmacokinetics, more in-depth methods 
to examine the influence of smoking on TDM, and simultaneous TDM of all drugs taken by the 
patients, should be performed. Moreover, new and larger studies investigating other variables that 
may affect TDM are needed to confirm and improve the predictive models proposed.     
   In conclusion, according to the results obtained, within inpatients admitted for a relapse of a SSD 
or a BD, smoking less than 10 cigarettes per day, valid alliance with mental health services (for SSD) 
and female sex (for BD) are strongly associated with good compliance with psychopharmacological 
therapy measured with TDM. Moreover, in this clinical setting, indirect self-assessed evaluation of 
adherence (MARS 10 items) is neither reliable nor predictive of compliance with therapies.  
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Figure 1 – MARS total scores subdivided according to TDM results.  
MARS: Medication Adherence Report Scale; SSD: Schizophrenia Spectrum Disorders; BD: Bipolar and related 
Disorders; TDM: Therapeutic Drug Monitoring; iR: in Range; bR: below the Range.  
  
Figure 2 – ROC Curves of MARS total scores using TDM as gold standard.  
 
ROC: Receiver Operating Characteristic; MARS: Medication Adherence Report Scale; TDM: Therapeutic 
Drug Monitoring; SSD: Schizophrenia Spectrum Disorders; BD: Bipolar and related Disorders.  
  
Table 1 - Sociodemographic, clinical, and psychopathological characteristics of the samples 
   SSD (n = 57) DB (n = 76) F/χ2 p-value† 
Socio-demographic variables         
Gender, N of females (%) 19 (33.3) 34 (44.7) 1.940 .164 
Age, years, mean (SD) 43.1 (13.5)  51.9 (14.4) 12.795 <.001 
Married, N (%)  9 (15.8) 36 (47.4)  14.400 <.001 
Working, N (%) 6 (10.5)  29 (38.2) 3.20 .074 
Education, years, mean (SD) 10.4 (3.2) 12.7 (3.7)  12.050 <.001 
Caucasic, N (%) 51 (89.5) 71 (93.4) .431 .512 
Clinical variables       
Duration of illness, mean (SD)  18.9 (11.7) 22.3 (12.3)  1.975 0.162 
More than five prior hospitalizations 
    for mental disorders, N (%)  
35 (61.4)  38 (50.0) 3.15 .076 
Compulsory admission for the present hospitalization, N (%) 11 (19.3) 15 (19.7) .103 .749 
Smoking (≥ 10 cigarettes/day), N (%) 34 (59.6)  47 (61.8) .027 .870 
Substance and alcohol abuse, N (%) 6 (10.5) 18 (23.7) 3.01 .083 
Medical chronic comorbidities, N (%) 24 (42.1) 44 (57.9) 3.92 .048 
Global Assessment of Functioning (GAF), mean (SD)* 51.3 (10.2) 62.9 (12.2) 29.971 <.001 
Service engagement scale, mean (SD) 19.7 (8.41) 16.5 (7.3) 3.347 .065 
Psychopathological variables        
BPRS-1, affect, mean (SD)  10.5 (4.1) 10.8 (4.7) .171 .679 
BPRS-2, negative symptoms, mean (SD) 8.7 (3.6) 7.2 (4.2) 3.593 .025 
BPRS-3, positive symptoms, mean (SD) 10.6 (3.9) 9.7 (4.7) 1.129 .290 
BPRS-4, activation, mean (SD) 7.8 (3.3) 9.0 (3.2) 5.819 .017 
BPRS-5, resistance, mean (SD)  7.7 (4.5) 8.0 (4.8) .582 .447 
Clinical Global Impression (CGI), mean (SD) 4.6 (0.9) 4.5 (0.9) .005 .942 
Drug treatment at the moment of the hospitalization        
Haloperidol, N (%)  16 (28.1) 7 (9.2) 8.10 .004 
Second generation antipsychotics, N (%)  35 (61.4) 58 (76.3) 2.89 .084 
Both first- and second-generation antipsychotics, N (%) 6 (10.5) - NA NA 
Antidepressants, N (%) 10 (17.5) 13 (17.1) .030 .862 
Mood stabilizers, N (%) 15 (26.3) 50 (65.8) 21.6 <.001 
Anxiolytics, N (%) 43 (75.4) 57 (75.0) .002 .964 
Polypharmacy, N (%)  47 (82.5) 70 (92.1) 2.22 .136 
UKU gravity, mean (SD) 0.3 (1.3) 0.2 (0.5) 1.61 .206 
Evaluation of psychopharmacological treatment adherence        
Therapeutic drug monitoring in range (TDM-iR), N (%) 29 (50.9) 42 (55.3) .129 .719 
Medication Adherence Report Scale (MARS), mean (SD)  5.6 (2.9) 5.6 (2.7) .008 .928 
 
SD: standard deviation; BPRS: Brief Psychiatric Rating Scale; UKU: Udvalg for Kliniske Undersøgelser - Side Effect Rating 
Scale; † uncorrected; * prior to hospitalization; NA: not applicable; Statistically significant different results are 
indicated in italics.  
  
Table 2 - Therapeutic drug monitoring results for each drug measured  
 
  TDM  
  iR  bR 
Antipsychotics  37 (50.0%) 37 (50.0%) 
Haloperidol [10.5%] 5 (35,7%) 9 (64.3%) 
Aripiprazole [15.0%] 7 (35,0%) 13 (65,0%) 
Clozapine [3.0%] 3 (75.0%) 1 (25.0%) 
Olanzapine [8.3%] 6 (54,5%) 5 (45,5%) 
Paliperidone [3.8%] 4 (80,0%) 1 (20,0%) 
Quetiapine [8.3%] 7 (63.6%) 4 (36,4%) 
Risperidone [6,8%] 5 (55.6%) 4 (44,4%) 
Mood stabilizers 35 (59.3%) 24 (40,7%) 
Lithium ion [21.1%] 12 (42.9%) 16 (57,1%) 
Valproic acid [21.8%] 22 (75.9%) 7 (24.1%) 
Carbamazepine [1.5%] 1 (50.0%) 1 (50%)  
 
TDM: therapeutic drug monitoring; iR: in range; bR: below the range; (%): percentage of TDM in range or below the 




Table 3 - Diagnostic characteristic of MARS total scores 
 
Therapeutic drug monitoring results were used as gold standards. (95% CI), CI: confidence interval; PPV: positive 
predictive value; NVP: negative predictive value; +LR: positive likelihood ratio; -LR: negative likelihood.  
  
Schizophrenia Spectrum Disorders (n = 57)  
MARS ≥ Sensitivity [%] Specificity [%] Accuracy [%]  PPV [%] NPP [%] +LR  -LR  
10 6.9 (0.9 - 22.8) 92.9 (76.5 - 99.1) 49.1 (35.6 - 62.7) 50.0 (13.1 - 86.9) 49.1 (45.5 - 52.6) 1.0 (0.2 - 6.4) 1.0 (0.9 - 1.2) 
9 20.7 (8.1 - 39.7) 85.7 (67.3 - 96.0) 52.6 (39.1 - 66.0) 60.0 (32.1 - 82.6) 51.1 (45.1 - 57.0) 1.5 (0.5 - 4.6) 0.9 (0.7 - 1.2) 
8 41.4 (23.5 - 61.1) 67.9 (47.7 - 84.1) 54.4 (40.7 - 67.6) 57.1 (40.1 - 72.7) 52.8 (42.9 - 62.5) 1.3 (0.7 - 2.6) 0.9 (0.6 - 1.3) 
7 44.8 (26.5 - 64.1) 60.7 (40.6 - 78.5) 52.6 (39.0 - 66.0) 54.2 (39.1 - 68.6) 51.5 (40.6 - 62.3) 1.1 (0.6 - 2.1) 0.9 (0.6 - 1.4) 
6 55.1 (35.7 - 73.6) 57.1 (37.2 - 75.5) 56.1 (42.4 - 69.3) 57.1 (43.8 - 69.6) 55.2 (42.4 - 67.3) 1.3 (0.8 - 2.2) 0.8 (0.5 - 1.3) 
5 65.5 (45.7 - 82.1) 42.9 (24.5 - 62.8) 54.4 (40.7 - 67.6) 54.3 (43.9 - 64.3) 54.6 (38.3 - 69.9) 1.2 (0.8 - 1.7) 0.8 (0.4 - 1.6) 
4 82.7 (64.2 - 94.2) 32.1 (15.9 - 52.4) 57.9 (44.1 - 70.9) 55.9 (48.2 - 63.1) 64.3 (40.8 - 82.5) 1.2 (0.9 - 1.7) 0.5 (0.2 - 1.4) 
3 86.2 (68.3 - 96.1) 25.0 (10.7 - 44.9) 56.1 (42.4 - 69.3) 54.4 (47.9 - 60.7) 63.6 (36.5 - 84.2) 1.2 (0.9 - 1.5) 0.6 (0.2 - 1.7) 
2 96.3 (81.0 - 99.9) 16.0 (4.5 - 36.1) 57.7 (43.2 - 71.3) 55.3 (50.7 - 59.9) 80.0 (32.4 - 97.1) 1.2 (1.0 - 1.4) 0.2 (0.0 - 1.9) 
1 100.0 (88.1 - 100.0) 10.7 (2.3 - 28.2) 56.1 (42.4 - 69.3) 53.7 (50.5 - 56.9) 100.0 (NA) 1.12 (NA) 0.00 (NA) 
0 100.0 (88.1 - 100.0) 0.0 (0.0 - 12.3) 50.9 (37.3 - 64.4) 50.9 (NA) NA 1.00 (NA) NA 
Bipolar Disorders (n = 76) 
MARS ≥ Sensitivity [%] Specificity [%] Accuracy [%]  PPV [%] NPP [%] +LR  -LR  
10 7.1(1.5 - 19.5) 94.1 (80.3 - 99.3) 46.1 (34.6 - 57.9) 60.0 (21.0 - 89.4) 45.1 (42.2 - 48.0) 1.2 (0.2 - 6.7) 1.0 (0.9 - 1.1) 
9 19.1 (8.6 - 34.1) 73.5 (55.6 - 87.1) 43.4 (32.1 - 55.3) 47.1 (27.8 - 67.3) 42.4 (36.4 - 48.6) 0.7 (0.3 - 1.7) 1.1 (0.9 - 1.4) 
8 35.7 (21.6 - 52.0) 67.7 (49.5 - 82.6) 50.0 (38.3 - 61.7) 57.7 (42.0 - 72.0) 46.0 (38.1 - 54.1) 1.1 (0.6 - 2.1) 1.0 (0.7 - 1.3) 
7 42.9 (27.7 - 59.0) 61.8 (43.6 - 77.8) 51.3 (39.6 - 63.0) 58.1 (44.4 - 70.6) 46.7 (37.6 - 55.9) 1.1 (0.7 - 2.0) 0.9 (0.6 - 1.3) 
6 47.6 (32.0 - 63.6) 55.9 (37.9 - 72.8) 51.3 (39.6 - 63.0) 57.1 (44.9 - 68.6) 46.3 (36.3 - 56.7) 1.1 (0.7 - 1.77) 0.9 (0.6 - 1.4) 
5 59.5 (43.3 - 74.4) 52.9 (35.1 - 70.2) 56.6 (44.7 - 67.9) 61.0 (50.3 - 70.7) 51.4 (39.5 - 63.2) 1.3 (0.8 - 2.0) 0.8 (0.5 - 1.2) 
4 78.6 (63.2 - 89.7) 32.4 (17.4 - 50.5) 57.9 (46.0 - 69.1) 58.9 (52.0 - 65.5) 55.0 (36.5 - 72.3) 1.2 (0.9 - 1.5) 0.7 (0.3 - 1.4) 
3 90.5 (77.4 - 97.3) 14.7 (5.0 - 31-1) 56.6 (44.7 - 67.9) 56.7 (52.5 - 60.9) 55.6 (26.7 - 81.1) 1.1 (0.9 - 1.3) 0.7 (0.2 - 2.2) 
2 97.6 (87.4 - 99.9) 0.0 (0.0 - 10.3) 54.4 (42.1 - 65.5) 54.6 (53.5 - 55.8) NA 0.98 (NA) NA 
1 100.0 (91.6 - 100.0) 0.0 (0.0 - 10.3) 55.3 (43.4 - 66.7) 55.3 (NA) NA 1.00 (NA) NA 
0 NA NA NA NA NA NA NA 
 
Table 4 Comparison between TDM-iR and TDM-bR in SSD and BD clinical groups 
 SSD DB 
 TDM-iR 
(n = 29; 50.9%) 
TDM-bR 
(n = 28; 49.1%) 
F/χ2 p-value† 
TDM-iR  
(n = 42; 55.3%) 
TDM-bR 
( n = 34; 44.7%) 
F/χ2 p-value† 
Sociodemographic variables         
Gender, F/M, % 57.9/47.4 42.1/52.6 .219 .640 70.6/42.9 29.4/57.1 4.777 .029 
Age, years, mean (SD) 40.9 (13.9) 45.4 (12.8) 1.602 .211 52.0 (15.3) 52.0 (15.3) .001 .978 
Married, Y/N, % 55.6/50.0 44.5/50.0 .000 1.000 58.3/52.5 41.7/47.5 .078 .780 
Working, Y/N % 50.0/51.0 50.0/49.0 .000 1.000 37.9/66.0 62.0/34.0 4.621 .032 
Education, years, mean (SD) 10.2 (3.1) 10.6 (3.4) .213 .646 12.5 (3.7) 12.8 (3.7) .127 .723 
Caucasic, Y/N, % 49.0/66.6 51.0/33.3 .149 .699 54.9/60.0 45.0/40.0 .000 1.000 
Clinical variables         
Duration of illness, mean (SD) 16.3 (12.4) 21.6 (10.4) 2.928 .092 22.7 (13.2) 21.8 (10.5) .122 .728 
More than five prior hospitalizations 
for mental disorder, Y/N, % 
51.4/50.0 48.6/50.0 .000 1.000 57.9/52.6 42.1/47.4 .053 .082 
Compulsory admission for the present  
hospitalization, Y/N, % 
54.5/50.0 45.5/50.0 .000 1.000 66.7/52.5 33.3/47.4 .492 .483 
Smoking, Y/N (%) 35.3/73.9 64.3/26.1 6.715 .010 42.5/75.9 57.5/27.1 6.757 .009 
Substance and alcohol abuse, Y/N (%) 83.3/47.1 16.7/53.0 1.561 .211 55.6/55.2 44.4/44.8 .000 1.000 
Medical chronic comorbidities, Y/N (%) 50.0/51.5 50.0/48.5 .000 1.000 54.6/56.3 45.5/43.8 .000 1.000 
Global Assessment of Functioning (GAF), mean (SD)* 54.3 (8.6) 48.3 (10.9) 5.467 .023 62.4 (12.6) 63.6 (11.7) .183 .670 
Service engagement scale (SES), mean (SD) 17.5 (8.3) 21.9 (8.1) 4.136 .047 15.6 (7.7) 17.5 (6.6) 1.237 .270 
Psychopathological variables         
BPRS-1, anxiety and depression, mean (SD) 11.1 (3.8) 9.8 (4.5) 1.448 .234 11.7 (4.8) 9.5 (4.3) 4.176 .045 
BPRS-2, negative symptoms, mean (SD) 9.2 (3.5) 8.4 (3.7) .745 .392 7.3 (4.0) 7.0 (4.4) .080 .778 
BPRS-3, though disorder, mean (SD) 9.7 (4.0) 11.5 (3.5) 3.141 .082 9.0 (4.6) 10.47 (4.7) 1.675 .200 
BPRS-4, activation, mean (SD) 7.0 (3.3) 8.7 (3.1) 3.735 .058 8.9 (3.5) 9.2 (2.8) .220 .640 
BPRS-5, hostility and suspiciousness, mean (SD) 6.8 (3.7) 8.6 (5.0) 2.313 .134 8.1 (5.1) 7.9 (4.3) .033 .856 
Clinical Global Impression (CGI), mean (SD) 4.5 (0.7) 4.7 (1.0) .954 .333 4.5 (0.9) 4.5 (0.9) .000 1.000 
Variables related to the psychopharmacological treatment         
Haloperidol, Y/N (%) 17.2/82.8 28.6/71.4 1.04 .308 42.9/56.2 57.1/43.5 .086 .769 
Second generation antipsychotics, Y/N (%) 89.3/10.7 53.6/46.4 9.74 .008 58.6/44.4 41.4/55.6 .617 .432 
Polypharmacy, Y/N (%) 75.9/24.1 89.3/10.7 1.77 .183 57.1/33.3 42.9/66.7 .487 .485 
UKU gravity, mean (SD) 0.1 (0.3) 0.5 (1.8) 1.559 .217 0.3 (0.5) 0.2 (0.5) .173 .678 
Medication Adherence Rating Scale (MARS), Mean (SD) 6.0 (2.7) 5.1 (3.1) 1.350 .250 5.8 (2.6) 5.5 (2.8) .258 .613 
SD: standard deviation; Y/N: yes/no; BPRS: Brief Psychiatric Rating Scale; UKU: Udvalg for Kliniske Undersøgelser - Side Effect Rating Scale; † uncorrected; * prior to 
hospitalization; Statistically significant different results are indicated in italics. 
  
Table 5 - Logistic regression  
  Exp B p-value 
SSD 
Smoking .195 .008 
SES .936 .077 
BD 
Smoking .273 .016 
Sex 2.671 .055 
 
SSD: schizophrenia spectrum disorders; BD: bipolar and related disorders; SES: service engagement scale; Smoking = 
smoking > 10 cigarettes a day.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
